share_log

翰森製藥:自願公告 - 四款創新藥續約納入2024國家醫保目錄

HANSOH PHARMA: VOLUNTARY ANNOUNCEMENT - FOUR INNOVATIVE DRUGS RENEWED IN THE 2024 NATIONAL REIMBURSEMENT DRUG LIST

HKEX ·  Nov 28, 2024 20:37

Summary by Moomoo AI

翰森製藥於2024年11月28日宣布,其四款創新藥品成功續約納入2024國家醫保目錄,這些藥品將於2025年1月1日正式執行。這四款藥品包括甲磺酸阿美替尼片、甲磺酸氟馬替尼片、伊奈利珠單抗注射液及聚乙二醇洛塞那肽注射液,分別針對非小細胞肺癌、慢性髓性白血病、視神經脊髓炎譜系疾病及糖尿病患者。這一舉措將進一步提高這些創新藥在患者中的可負擔性和可及性。此外,翰森製藥的其他創新藥品如培莫沙肽注射液和艾米替諾福韋片已納入2023國家醫保目錄,協議有效期至2025年12月31日;嗎啉硝唑氯化鈉注射液則已納入國家醫保常規目錄乙類。這些藥品的納入有助於提升公司在醫療市場的競爭力,並為患者提供更多的治療選擇。翰森製藥的董事會由鍾慧娟女士擔任主席,並由多位執行董事及獨立非執行董事組成。公司將繼續致力於創新藥物的研發和市場拓展,以滿足不斷增長的醫療需求。
翰森製藥於2024年11月28日宣布,其四款創新藥品成功續約納入2024國家醫保目錄,這些藥品將於2025年1月1日正式執行。這四款藥品包括甲磺酸阿美替尼片、甲磺酸氟馬替尼片、伊奈利珠單抗注射液及聚乙二醇洛塞那肽注射液,分別針對非小細胞肺癌、慢性髓性白血病、視神經脊髓炎譜系疾病及糖尿病患者。這一舉措將進一步提高這些創新藥在患者中的可負擔性和可及性。此外,翰森製藥的其他創新藥品如培莫沙肽注射液和艾米替諾福韋片已納入2023國家醫保目錄,協議有效期至2025年12月31日;嗎啉硝唑氯化鈉注射液則已納入國家醫保常規目錄乙類。這些藥品的納入有助於提升公司在醫療市場的競爭力,並為患者提供更多的治療選擇。翰森製藥的董事會由鍾慧娟女士擔任主席,並由多位執行董事及獨立非執行董事組成。公司將繼續致力於創新藥物的研發和市場拓展,以滿足不斷增長的醫療需求。
Hansen Pharmaceuticals announced on November 28, 2024 that its four innovative medicines have been successfully renewed to the 2024 National Health Insurance Catalog, which will be officially implemented on January 1, 2025. The four drugs, which include Amethinic Thesulfate Tablets, Fluormatinic Acid Tablets, Ineryl Bead Single Injection, and Polyethylene Glycerate Injection, are targeted at patients with non-small cell lung cancer, chronic myeloid leukemia, neuromyelitis spectrum disease, and diabetes. This move will further enhance the affordability and accessibility of these innovative drugs among patients.In addition, other innovative medicines from Hanssen Pharmaceuticals, such as pemosapeptide injections and amitinofovir tablets, have been included in the 2023 National Health Catalogue. The agreement is valid until December 31, 2025; Morphinitazole Sodium Chloride Injection has been included in the National Health Directory...Show More
Hansen Pharmaceuticals announced on November 28, 2024 that its four innovative medicines have been successfully renewed to the 2024 National Health Insurance Catalog, which will be officially implemented on January 1, 2025. The four drugs, which include Amethinic Thesulfate Tablets, Fluormatinic Acid Tablets, Ineryl Bead Single Injection, and Polyethylene Glycerate Injection, are targeted at patients with non-small cell lung cancer, chronic myeloid leukemia, neuromyelitis spectrum disease, and diabetes. This move will further enhance the affordability and accessibility of these innovative drugs among patients.In addition, other innovative medicines from Hanssen Pharmaceuticals, such as pemosapeptide injections and amitinofovir tablets, have been included in the 2023 National Health Catalogue. The agreement is valid until December 31, 2025; Morphinitazole Sodium Chloride Injection has been included in the National Health Directory Class B. The inclusion of these drugs helps increase the company's competitiveness in the medical market and provides patients with more treatment options.THE BOARD OF HANSEN PHARMACEUTICALS IS CHAIRED BY MS. CHUNG WAI JUAN AND CONSISTS OF SEVERAL EXECUTIVE DIRECTORS AND INDEPENDENT NON-EXECUTIVE DIRECTORS. The Company will continue to focus on R&D and market expansion of innovative medicines to meet growing medical needs.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more